Lonza and Chr. Hansen in biotech joint venture to accelerate momentum in microbiome

Niederer Kraft Frey advised Chr. Hansen Holding A/S , a leading global bioscience company listed on OMX, in its agreement with Lonza AG, a leading pharma contract manufacturing company listed on SIX, to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland.

The NKF team was led by Corporate/M&A partners Philipp Haas and Ulysses von Salis, working with partner Clara-Ann Gordon (Technology), partner Nicolas Birkhäuser (Antitrust/Competition and IP) and associates Julia Tolstova, Shu Bernet-Zhang, Samuel Hochstrasser (Corporate/M&A) and Victor Stancescu (Technology).